 Shares of Ocugen Inc. OCGN, -2.03 sank 6.9 premarket, after the biotechnology company said the U.S. Food and Drug Administration placed a clinical hold on the Phase 23 study of its COVID-19 vaccine candidate Covaxin. Ocugen said the hold was the result of its decision to temporarily pause dosing participants in the study while it evaluates World Health Organization statements following their inspection of Bharat Biotech International Ltd. 